Non-cystic fibrosis bronchiectasis

Journal of the Royal College of Physicians of Edinburgh

Volumn 41, Issue 2, 2011, Pages 132-139

  Smith, M P ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Bronchiectasis; Exacerbations; Infection; Management

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BECLOMETASONE; CORTICOSTEROID; ERYTHROMYCIN; FLUTICASONE; GENTAMICIN; MACROLIDE; MANNITOL; MUCOLYTIC AGENT; PLACEBO; SODIUM CHLORIDE; TOBRAMYCIN;

BREATHING EXERCISE; BRONCHIECTASIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; HUMAN; HUMIDIFIER; LUNG CLEARANCE; NON CYSTIC FIBROSIS BRONCHIECTASIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT MONITORING; PERCUSSION; PHYSIOTHERAPY; POSTURAL DRAINAGE; PREVALENCE; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BRONCHI; BRONCHIECTASIS; DEVELOPING COUNTRIES; HUMANS; SOCIOECONOMIC FACTORS;

EID: 80052702596     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2011.217     Document Type: Review

References (65)

1. Laennec R. A treatise in the diseases of the chest and on mediate auscultation. 4th ed. London: Longman; 1834.
2. Warner WP. Bronchiectasis: aetiology, diagnosis and treatment. Can Med Assoc J 1932; 27:583-93.
3. King PT, Holdsworth SR, Freezer NJ et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006; 100:2183-9. doi:10.1016/j.rmed.2006.03.012
4. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005; 128:739-45. doi:10.1378/ chest.128.2.739
5. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003; 14:488-92. doi:10.1016/j.ejim.2003.10.002
6. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65(Suppl 1):i1-58. doi:10.1136/thx.2010.136119
7. Marostica PJ, Fischer GB. Non-cystic-fibrosis bronchiectasis: a perspective from South America. Paediatr Respir Rev 2006; 7:275-80. doi:10.1016/j.prrv.2006.04.008
8. Babayigit A, Olmez D, Uzuner N et al. A neglected problem of developing countries: noncystic fibrosis bronchiectasis. Ann Thorac Med 2009; 4:21-4. doi:10.4103/1817-1737.44781
9. Weycker D, Edelsberg J, Oster G et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12:205-9. doi:10.1097/01.cpm.0000171422.98696.ed
10. Nicotra MB, Rivera M, Dale AM et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995; 108:955-61. doi:10.1378/chest.108.4.955
11. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101:1163-70. doi:10.1016/j. rmed.2006.11.008
12. Morrissey BM, Harper RW. Bronchiectasis: sex and gender considerations. Clin Chest Med 2004; 25:361-72. doi:10.1016/j. ccm.2004.01.011
13. Seitz AE, Olivier KN, Steiner CA et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138:944-9. doi:10.1378/chest.10-0099
14. Roberts ME, Lowndes L, Milne DG et al. Socioeconomic deprivation, readmissions, mortality, and acute exacerbations of bronchiectasis. Intern Med J 2011; epub ahead of print 8 Feb. doi:10.1111/j.1445-5994.2011.02444.x
15. Angrill J, Agustí C, de Celis R et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164:1628-32.
16. Hill AT, Campbell EJ, Hill SL et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-95. doi:10.1016/ S0002-9343(00)00507-6
17. Cole PJ. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147:6-15.
18. King PT, Holdsworth SR, Freezer NJ et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007; 101:1633-8. doi:10.1016/j.rmed.2007.03.009
19. Angrill J, Agustí C, de Celis R et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15-9. doi:10.1136/thorax.57.1.15
20. Pasteur MC, Helliwell SM, Houghton SJ et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162(4 Pt 1):1277-84.
21. Wickremasinghe M, Ozerovitch LJ, Davies G et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005; 60:1045-51. doi:10.1136/thx.2005.046631
22. Fowler SJ, French J, Screaton NJ et al. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur Respir J 2006; 28:1204-10. doi:10.1183/09031936.06.00149805
23. Murray MP, Pentland JL, Turnbull K et al. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:361-4. doi:10.1183/09031936.00163208
24. Naidich DP, McCauley DI, Khouri NF et al. Computed tomography of bronchiectasis. J Comput Assist Tomogr 1982; 6:437-44. doi:10.1097/00004728-198206000-00001
25. Swinson DR, Symmons D, Suresh U et al. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997; 36:689-91. doi:10.1093/rheumatology/36.6.689
26. Patel IS, Vlahos I, Wilkinson TM et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:400-7. doi:10.1164/ rccm.200305-648OC
27. Sumikawa H, Johkoh T, Colby TV et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008; 177:433-9. doi:10.1164/ rccm.200611-1696OC
28. Kapur N, Karadag B. Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries. Paediatr Respir Rev 2010; 12:91-6. doi:10.1016/j.prrv.2010.10.010
29. Finklea JD, Khan G, Thomas S et al. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med 2010; 104:816-21. doi:10.1016/j.rmed.2009.11.021
30. Verra F, Escudier E, Lebargy F et al. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J Respir Crit Care Med 1995; 151(3 Pt 1):630-4.
31. Chang CC, Singleton RJ, Morris PS et al. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009; 2:CD006316.
32. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:1086-92. doi:10.1183/09031936.00055509
33. O'Neill B, Bradley JM, McArdle N et al. The current physiotherapy management of patients with bronchiectasis: a UK survey. Int J Clin Pract 2002; 56:34-5.
34. Eaton T, Young P, Zeng I et al. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in noncystic fibrosis bronchiectasis. Chron Respir Dis 2007; 4:23-30. doi:10.1177/1479972306074481
35. Thompson CS, Harrison S, Ashley J et al. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002; 57:446-8. doi:10.1136/thorax.57.5.446
36. Conway JH, Fleming JS, Perring S et al. Humidification as an adjunct to chest physiotherapy in aiding tracheo-bronchial clearance in patients with bronchiectasis. Respir Med 1992; 86:109-14. doi:10.1016/S0954-6111(06)80225-8
37. Hasani A, Chapman TH, McCool D et al. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis 2008; 5:81-6. doi:10.1177/1479972307087190
38. Shibuya Y, Wills PJ, Cole PJ. Effect of osmolality on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respirology 2003; 8:181-5. doi:10.1046/j.1440-1843.2003.00454.x
39. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005; 99:27-31. doi:10.1016/j. rmed.2004.05.006
40. Daviskas E, Anderson SD, Eberl S et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999; 159:1843-8.
41. Daviskas E, Anderson SD, Eberl S et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001; 119:414-21. doi:10.1378/chest.119.2.414
42. Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005; 10:46-56. doi:10.1111/j.1440-1843.2005.00659.x
43. O'Donnell AE, Barker AF, Ilowite JS et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113:1329-34. doi:10.1378/ chest.113.5.1329
44. Gaga M, Bentley AM, Humbert M et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53:685-91. doi:10.1136/thx.53.8.685
45. Tsang KW, Ho PL, Lam WK et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998; 158:723-7.
46. Tsang KW, Tan KC, Ho PL et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60:239-43. doi:10.1136/ thx.2002.003236
47. Elborn JS, Johnston B, Allen F et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992; 86:121-4. doi:10.1016/S0954-6111(06)80227-1
48. Tsang KW, Ho PI, Chan KN et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13:361-4. doi:10.1183/09031936.99.13236199
49. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004; 59:540-1.
50. Cymbala AA, Edmonds LC, Bauer MA et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4:117-22. doi:10.2165/00151829-200504020-00005
51. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011; 105:946-9. doi:10.1016/j.rmed.2011.01.009
52. Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. Br Med J 1957; 2:255-9.
53. Currie DC, Garbett ND, Chan KL et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990; 76:799-816.
54. Sobel S, Lichter EA, Davis JC et al. Adverse reactions to tetracycline, penicillin and an oleandomycin-penicillin mixture used in the long-term therapy of chronic pulmonary disease. Am J Med Sci 1962; 243:341-53. doi:10.1097/00000441-196203000-00009
55. Palmer LB, Smaldone GC, Simon SR et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998; 26:31-9. doi:10.1097/00003246-199801000-00013
56. Barker AF, Couch L, Fiel SB et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162(2 Pt 1):481-5.
57. Drobnic ME, Sune P, Montoro JB et al. Inhaled tobramycin in noncystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39:39-44. doi:10.1345/aph.1E099
58. Murray MP, Govan JR, Doherty CJ et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183:491-9. doi:10.1164/rccm.201005-0756OC
59. Bagheri R, Haghi SZ, Fattahi Masoum SH et al. Surgical management of bronchiectasis: analysis of 277 patients. Thorac Cardiovasc Surg 2010; 58:291-4. doi:10.1055/s-0030-1249941
60. Hill SL, Stockley RA. Effect of short and long term antibiotic response on lung function in bronchiectasis. Thorax 1986; 41:798-800. doi:10.1136/thx.41.10.798
61. Pines A, Raafat H, Plucinski K et al. Cephaloridine compared with penicillin and streptomycin in chronic purulent bronchitis. Controlled trials of increasing dosage of cephaloridine. Br J Dis Chest 1967; 61:101-10. doi:10.1016/S0007-0971(67)80033-0
62. Davies BI, Maesen FP, van Noord JA. Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime. J Antimicrob Chemother 1983; 12(Suppl A):1-8.
63. Patterson JE, Hewitt O, Kent L et al. Acapella versus 'usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis 2007; 4:67-74. doi:10.1177/1479972306075483
64. Murray MP, Turnbull K, Macquarrie S et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33:312-7. doi:10.1183/09031936.00122508
65. Wilson CB, Jones PW, O'Leary CJ et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997 Aug; 156(2 Pt 1):536-41.